New combo therapy aims to control aggressive lymphoma
NCT ID NCT05495464
First seen Mar 05, 2026 · Last updated Apr 29, 2026 · Updated 5 times
Summary
This early-phase study tests whether a combination of two drugs (acalabrutinib and rituximab) followed by a special cell therapy (brexucabtagene autoleucel) can help control high-risk mantle cell lymphoma in people who have not yet been treated. About 22 participants will receive the treatment, and researchers will monitor for serious side effects within 30 days after the cell infusion. The goal is to see if this approach is safe and effective at managing the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.